U.S. Department of Health & Human Services
07/06/2022 | Press release | Distributed by Public on 07/06/2022 11:28
Selected Adverse Events Reported after COVID-19 Vaccination
Multiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As a result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.
As of June 30, 2022, there have been 1,011 preliminary reports in VAERS among people younger than age 18 years under review for potential cases of myocarditis and pericarditis. Of these, 261 remain under review. Through confirmation of symptoms and diagnostics by provider interview or review of medical records, 659 reports have been verified to meet CDC's working case definition for myocarditis. See below for counts of verified reports of myocarditis by age group.
5-11 years: 22 verified reports of myocarditis after 19,682,799 doses administered
12-15 years: 341 verified reports of myocarditis after 23,794,975 doses administered
16-17 years: 296 verified reports of myocarditis after 12,951,176 doses administered
As the COVID-19 vaccines are authorized for younger children, CDC and FDA will continue to monitor for and evaluate reports of myocarditis and pericarditis after COVID-19 vaccination and will share more information as it becomes available. Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19 vaccination.